- Home
- PRTC
PRTC
PureTech Health plc
as 11-07-2024 3:36pm EST
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
| Founded: | 2015 | Country: | United States |
| Employees: | 90 | City: | N/A |
| Market Cap: | 504.9M | IPO Year: | N/A |
| Target Price: | $45.00 | AVG Volume (30 days): | 3.4K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.08 - $34.00 | Next Earning Date: | 08-28-2024 |
| Revenue: | $468,000 | Revenue Growth: | -96.01% |
| Revenue Growth (this year): | -19.61% | Revenue Growth (next year): | 139.60% |
Latest PureTech Health plc News
PRTC Breaking Stock News: Dive into PRTC Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
Business Wire
9 days ago
PureTech to Present at Two Upcoming Investor Conferences
MT Newswires
18 days ago
PureTech Health's Seaport Therapeutics Closes $225 Million in Oversubscribed Series B Financing
BioPharma Dive
18 days ago
PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Business Wire
18 days ago
PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
The Wall Street Journal
a month ago
Corrections & Amplifications
Business Wire
a month ago
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
Business Wire
a month ago
PureTech to Present at CHEST 2024 Annual Meeting
Compare PRTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTC PureTech Health plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.